Richard Durrance, MD
Pulmonary Disease · Spokane, WANPI 1598128670
Payments from drug & device makers
Across 93 payments — averaging $32.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$803
- United Therapeutics Corporation$421
- AstraZeneca$402
- GSK$205
- Actelion Pharmaceuticals US, Inc.$182
- Boehringer Ingelheim$143
- plus $895 from 13 others
What the payments were for
- Speaking & faculty fees$181%
- Travel & lodging$70023%
- Food & beverage$2,17571%
- Education$1585%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 8 | $803 |
| United Therapeutics Corporation | 14 | $421 |
| AstraZeneca | 16 | $402 |
| GSK | 15 | $205 |
| Actelion Pharmaceuticals US, Inc. | 5 | $182 |
| Boehringer Ingelheim | 2 | $143 |
| Regeneron Healthcare Solutions, Inc. | 4 | $121 |
| Electromed, Inc. | 2 | $115 |
| Mylan Specialty L.p. | 4 | $94 |
| Merck | 3 | $87 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Sanofi | 4 | $75 |
| Pfizer | 1 | $73 |
| Amgen | 4 | $72 |
| Baxter Healthcare | 2 | $51 |
| Philips North America LLC | 3 | $48 |
| Vifor Pharma, Inc. | 2 | $44 |
| Medline Industries LP | 2 | $18 |
| BD | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUMISITE$615
- OFEV$125
How this compares
$3,051 in reported general payments places this provider in the 70th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 16 | $397,665 |
| OfevNintedanib Esylate | 18 | $228,012 |
| TracleerBosentan | 12 | $147,496 |
| Dupixent PenDupilumab | 36 | $130,364 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 127 | $102,485 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 91 | $86,935 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 107 | $74,670 |
| Spiriva RespimatTiotropium Bromide | 71 | $48,628 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 67 | $35,907 |
| Bosentan | 11 | $34,504 |
| Spiriva HandihalerTiotropium Bromide | 45 | $30,810 |
| SymbicortBudesonide/Formoterol Fumarate | 76 | $24,555 |
| DuleraMometasone/Formoterol | 52 | $21,818 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $20,742 |
| Advair HfaFluticasone Propion/Salmeterol | 35 | $14,474 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $143 | $360,294210 claims |
| Actelion Pharmaceuticals US, Inc.Tracleer, Bosentan | $182 | $182,00023 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $205 | $173,903277 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $402 | $111,490167 claims |
| MerckDulera | $87 | $21,81852 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 275 pulmonary disease providers in Washington.
Other pulmonary disease in Spokane
- Jiten PatelSpokane$396K
- Allison LambertSpokane$352K
- Jonathan DanarajSpokane$142K
- Bryan AndersonSpokane$56K
- Griffith LiangSpokane$13K
- Fatima AjazSpokane$6K
- Benjamin ArthursSpokane$6K
- Harshwant GroverSpokane$6K
- Peter ChenSeattle$2.7M
- Tomasz ZiedalskiEverett$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.